Tag - Cyclacel

Brookline Capital Markets initiated coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $22 price target. The stock closed at $4.12 on May 18. Cyclacel is developing small molecule drugs targeting...